Home » Stocks » REGENXBIO Inc.


Stock Price: $33.90 USD 0.88 (2.67%)
Updated Aug 10, 2020 4:00 PM EDT - Market closed
After-hours: $34.00 +0.10 (0.30%) Aug 10, 5:11 PM

Stock Price Chart

Key Info

Market Cap 1.27B
Revenue (ttm) 60.68M
Net Income (ttm) -134.85M
Shares Out 37.33M
EPS (ttm) -3.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 10, 2020
Last Price $33.90
Previous Close $33.02
Change ($) 0.88
Change (%) 2.67%
Day's Open 32.79
Day's Range 32.60 - 34.33
Day's Volume 273,564
52-Week Range 20.03 - 54.97

More Stats

Market Cap 1.27B
Enterprise Value 1.01B
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 37.33M
Float 27.22M
EPS (basic) -3.65
EPS (diluted) -3.64
FCF / Share -3.31
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 4.27M
Short Ratio 11.32
Short % of Float 18.71%
Beta 0.99
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 20.86
PB Ratio 3.10
Revenue 60.68M
Operating Income -155.75M
Net Income -134.85M
Free Cash Flow -123.35M
Net Cash 260.42M
Net Cash / Share 6.98
Gross Margin -160.18%
Operating Margin -256.69%
Profit Margin -222.20%
FCF Margin -203.28%
ROA -19.89%
ROE -30.22%
ROIC -36.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 5
Overweight 1
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(85.84% upside)
Current: $33.90
Target: 63.00
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-83.88%2002.42%126.48%-39.52%23.99%0.54%-
Gross Profit26.992098.683.736.095.115.76
Operating Income-14988.10-75.89-65.34-23.14-3.68-4.76
Net Income-94.7399.94-73.17-62.97-22.81-4.00-5.39
Shares Outstanding36.6933.4329.8826.419.172.642.32
Earnings Per Share-2.582.73-2.45-2.38-2.59-1.82-2.50
Operating Cash Flow-108105-57.99-48.56-22.52-2.40-3.01
Capital Expenditures-11.72-13.28-7.16-8.15-0.52--
Free Cash Flow-11991.37-65.15-56.71-23.04-2.40-3.01
Cash & Equivalents29832116189.781141.121.12
Total Debt11.305.85---2.40-
Net Cash / Debt28631516189.78114-1.281.12
Book Value450509183162217-18.29-13.92
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name REGENXBIO Inc.
Country United States
Employees 257
CEO Kenneth T. Mills

Stock Information

Ticker Symbol RGNX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: RGNX
IPO Date September 17, 2015


REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II; RGX-111, which is in Phase I clinical trial for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is in Phase I/II clinical trials to treat homozygous familial hypercholesterolemia. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop vectorized antibodies for the treatment of neurodegenerative diseases. The company was formerly known as ReGenX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.